Lucid Diagnostics Inc. reported fourth‑quarter 2025 results, posting $1.5 million in revenue—up 25% from $1.197 million in Q4 2024—and a net loss of $16.266 million, compared with a $11.541 million loss in the prior year. The company’s revenue beat analyst expectations of $1.39 million, driven by a 24% sequential rise in EsoGuard® test volumes and growing physician adoption across health systems.
Full‑year 2025 revenue reached $4.706 million, a 9% increase over $4.346 million in 2024, while the net loss widened to $58.010 million from $45.529 million a year earlier. The broader loss reflects elevated commercialization spending—$15.5 million in operating expenses for Q4 2025—and continued investment in sales, marketing, reimbursement, and operational scale.
The company processed 3,664 EsoGuard® tests during the quarter and secured a contract with the U.S. Department of Veterans Affairs, expanding its commercial footprint. Management highlighted that the VA agreement, combined with ongoing Medicare coverage efforts, is expected to accelerate test volumes and improve reimbursement prospects.
Lucid’s gross profit margin for the quarter was –41.73%, underscoring the early‑stage nature of its commercial operations. The negative margin is driven by high operating costs relative to revenue, a common feature for companies investing heavily in market penetration.
Investors reacted positively to the results, with the stock rising 2.52% in pre‑market trading. The market’s enthusiasm was largely driven by the revenue beat and the strategic significance of the VA contract, which signals a broader acceptance of the EsoGuard® test in large integrated health systems.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.